Last reviewed · How we verify
Rocuronium 1.2
Rocuronium is a non-depolarizing neuromuscular blocking agent that competitively antagonizes acetylcholine at the nicotinic acetylcholine receptor on the motor endplate.
Rocuronium is a non-depolarizing neuromuscular blocking agent that competitively antagonizes acetylcholine at the nicotinic acetylcholine receptor on the motor endplate. Used for Neuromuscular blockade during general anesthesia for intubation and surgical procedures, Facilitation of mechanical ventilation in intensive care settings.
At a glance
| Generic name | Rocuronium 1.2 |
|---|---|
| Sponsor | Ain Shams University |
| Drug class | Non-depolarizing neuromuscular blocking agent |
| Target | Nicotinic acetylcholine receptor |
| Modality | Small molecule |
| Therapeutic area | Anesthesiology |
| Phase | Phase 3 |
Mechanism of action
Rocuronium binds to nicotinic acetylcholine receptors at the neuromuscular junction, preventing acetylcholine from binding and causing muscle depolarization. This results in paralysis of skeletal muscles, making it useful during anesthesia for intubation and surgical procedures. The drug is a steroidal compound with intermediate duration of action.
Approved indications
- Neuromuscular blockade during general anesthesia for intubation and surgical procedures
- Facilitation of mechanical ventilation in intensive care settings
Common side effects
- Histamine release (flushing, hypotension, tachycardia)
- Prolonged neuromuscular blockade
- Anaphylaxis
- Bronchospasm
Key clinical trials
- Comparison of the Effects of Total Intravenous Anaesthesia With Target-Controlled Infusion (TCI) and Inhalation Anaesthesia on Airway Complications During Extubation and in the Early Postoperative Period in Thyroidectomy Surgery (NA)
- Developing a Physiology-Pharmacodynamic Model of Rocuronium Dose and Cardiac Output to Investigate the Onset Time of Neuromuscular Relaxation (PHASE4)
- Anesthesia Management in Endovascular Therapy for Ischemic Stroke - 2 (NA)
- Optimisation Strategy for Emergency Tracheal Intubation (NA)
- Minimal Flow Anesthesia and Infection Risk (NA)
- Use of Sugammadex for Reversal of Paralysis in Microlaryngoscopy (PHASE4)
- Effects Of Anaesthesia on Intraocular Pressure in Robotic Prostate Surgery (NA)
- Paravertebral Nerve Blocks in Neonates (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rocuronium 1.2 CI brief — competitive landscape report
- Rocuronium 1.2 updates RSS · CI watch RSS
- Ain Shams University portfolio CI